Rafferty Asset Management, LLC Puma Biotechnology, Inc. Transaction History

Rafferty Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$6.63 - $9.39 $339,038 - $480,176	-51,137 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$8.98 - $11.6 $597,888 - $772,328	-66,580 Reduced 56.56%	51,137 $469,000
Q1 2021 May 10, 2021	BUY	$9.38 - $13.63 $876,908 - $1.27 Million	93,487 Added 385.83%	117,717 $1.14 Million
Q4 2020 Feb 10, 2021	SELL	$7.78 - $12.13 $508,026 - $792,076	-65,299 Reduced 72.94%	24,230 $249,000
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $385,291 - $451,804	40,557 Added 82.82%	89,529 $903,000
Q2 2020 Aug 07, 2020	BUY	$7.01 - $13.24 $217,464 - $410,731	31,022 Added 172.82%	48,972 $511,000
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $844,967 - $1.96 Million	-134,549 Reduced 88.23%	17,950 $151,000
Q4 2019 Feb 10, 2020	SELL	$6.5 - $10.73 $526,909 - $869,805	-81,063 Reduced 34.71%	152,499 $1.33 Million
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $1.03 Million - $1.52 Million	-118,198 Reduced 33.6%	233,562 $2.51 Million
Q2 2019 Aug 09, 2019	BUY	$12.3 - $35.76 $3.26 Million - $9.47 Million	264,904 Added 304.99%	351,760 $4.47 Million
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $1.8 Million - $3.68 Million	86,856 New	86,856 $3.37 Million

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $138M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.